Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.

导出 OA

翻译打印收藏纠错

作者： Hiroyuki,Nishiyama ^[1] ; Yoshiaki,Yamamoto ^[2] ; Naoto,Sassa ^[3] ; Kazuo,Nishimura ^[4] ; Kiyohide,Fujimoto ^[5] ; Satoshi,Fukasawa ^[6] ; Minato,Yokoyama ^[7] ; Hideki,Enokida ^[8] ; Kenichi,Takahashi ^[9] ; Yoshinobu,Tanaka ^[9] ; Kentaro,Imai ^[10] ; Takashi,Shimamoto ^[9] ; Rodolfo,Perini ^[10] ; Tara,Frenkl ^[10] ; Dean,Bajorin ^[11] ; Joaquim,Bellmunt ^[12]

作者单位： University of Tsukuba Hospital, 2 Chome-1-1 Amakubo, Tsukuba, Ibaraki, 305-8576, Japan. nishiuro@md.tsukuba.ac.jp. ^[1] Yamaguchi University Hospital, 1 Chome-1-1 Minamikogush, Ube, Japan. ^[2] Nagoya University Hospital, 65 Tsurumaicho, Showa Ward, Nagoya, Japan. ^[3] Osaka International Cancer Institute, 3 Chome-1-6 9 Otemae, Chuo Ward, Osaka, Japan. ^[4] Nara Medical University Hospital, 840 Shijocho, Kashihara, Japan. ^[5] Chiba Cancer Center, 666-2 Nitonacho, Chiba, Japan. ^[6] Medical Hospital, Tokyo Medical and Dental University, 1 Chome-5-45 Yushima, Tokyo, Japan. ^[7] Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan. ^[8] MSD K.K., Kitanomaru Square, 1-13-12, Kudan Kita, Tokyo, Japan. ^[9] Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ, USA. ^[10] Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA. ^[11] PSMAR-IMIM Research Institute, Carrer del Dr. Aiguader, 88, Barcelona, Spain. ^[12] Harvard Medical School, 25 Shattuck St, Boston, MA, USA. ^[13]

关键词 Advanced urothelial cancer Immune checkpoint blockade Japanese KEYNOTE-045 Pembrolizumab